BENITEC BIOPHARMA

NASDAQ: BNTC | ASX: BLT

PATHWAY TO VALUE CREATION

Corporate Presentation

24 April 2018

Greg West, Chief Executive Officer

SAFE HARBOR STATEMENT

This presentation contains "forward-looking statements" within the meaning of section 27A of the US Securities Act of 1933 and section 21E of the US Securities Exchange Act of 1934. Benitec has tried to identify such forward-looking statements by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements. Such statements include, but are not limited to, any statements relating to Benitec's pipeline of ddRNAi-based therapeutics, including the initiation, progress and outcomes of clinical trials and any other statements that are not historical facts. Such forward-looking statements involve risks and uncertainties, including, but not limited to, risks and uncertainties relating to the difficulties or delays in our plans to develop and potentially commercialize our product candidates, the timing of the initiation and completion of preclinical and clinical trials, the timing of patient enrolment and dosing in clinical trials, the timing of expected regulatory filings, the clinical utility and potential attributes and benefits of ddRNAi and our product candidates, potential future out-licenses and collaborations, our intellectual property position and duration of our patent portfolio, the ability to procure additional sources of financing and other risks detailed from time to time in filings that Benitec makes with US Securities and Exchange Commission, including our most recent annual report on Form 20-F and our reports on Form 6-K. Such statements are based on management's current expectations, but actual results may differ materially due to various factors, including those risks and uncertainties mentioned or referred to in this presentation. Accordingly, you should not rely on those forward-looking statements as a prediction of actual future results.

BENITEC BIOPHARMA

BUSINESS OVERVIEW



Proven Technology

First company into human clinical studies under a US IND with systemically delivered non-withdrawable RNAi (TT-034)

Robust Pipeline

Assets in oncology (Phase 2 entry, 1Q18), orphan genetic disorders (Phase 1/2a entry, 1Q19), retinal disease, and infectious disease.

Valuable Products

Human therapeutic products for commercialization, partnering, and collaborations

Benitec has created a novel combination of gene therapy and gene silencing to change treatment paradigms of human disease

BENITEC BIOPHARMA

HIGHLIGHTS

Programs advancing to clinic	EGFR-targeted gene silencing therapy confirmatory Phase 2 trial initiated in Q1 2018	Unique 'silence and replace' therapeutic designed to treat OPMD with IND filing in Q1 2019	Other programs could be clinic-ready in late 2019
Capital markets access	Listed on ASX (2002, BLT) and NASDAQ (2015, BNTC)	US$50M capital raised since 2014	US shelf registration statement filed June 2017
Strong in-house capabilities	19 staff with scientific operations in Hayward CA, including 9 PhDs with deep gene therapy expertise	In-house manufacturing expertise for process optimization and scalability	Extensive commercial and drug development expertise

BENITEC BIOPHARMA

CORPORATE SNAPSHOT

KEY SHAREHOLDER DETAILS	AUSTRALIA Listed ASX 2002: BLT	US Listed NASDAQ 2015: BNTC/BNTCW
Share Price as of 31st December, 2017: (ADS ratio 20:1)	A$0.20	US$2.96
52 week high/low as of 31st December, 2017	A$0.28/A$0.105	US$5.48 / US$1.39 (ADS)
Average daily volume (6 months to 31st December, 2017)	151,462 shares	49,667
Market Capitalization as of 31st December, 2017 (all shares)	A$41M	US$32M
Issued ordinary shares as of 31st December, 2017	205,142,734	--
Total options and warrants on issue as of 31st December, 2017	43,368,203	
Insider holdings – Nant Capital LLC	29%	
Cash balance as of 31st December, 2017	A$10.3M	
Net assets as of 31st December, 2017	A$17.2M	
Net loss as of 31st December, 2017	A$5.8M	
Capital raised	US$50m since 2014	
US SEC shelf registration	June 2017	
Facilities	Corporate Sydney, Australia	Scientific Operations Hayward, California

BENITEC BIOPHARMA

EXPERIENCED EXECUTIVE TEAM

Greg West
Chief Executive Officer

- Former CFO of Benitec Biopharma
- Prior roles as NED, CEO, CFO at a number of public companies
- Background at PriceWaterhouse, Bankers Trust, Deutsche Bank

Bryan Dulhunty
Chief Financial Officer

- Chairman of ASX listed Cryosite Ltd
- Former Executive Chairman, Viralytics
- Prior roles as NED, MD, CFO and Company Secretary of a number of listed and non-listed biotech companies

Dr. David Suhy
Chief Scientific Officer

- Former SVP of Research & Development, Benitec Biopharma
- Prior roles at Tacere Therapeutics, Antara Biosciences and PPD Discovery

Georgina Kilfoil
Chief Development Officer

- Former VP of Clinical Operations, Benitec Biopharma
- Prior roles at Anthera Pharmaceuticals, InClin and Peninsula Pharmaceuticals

BENITEC BIOPHARMA

VALUE DRIVERS

And path to value creation

Value Drivers

- One year major value inflection points include initial data readout from Phase 2 oncology study and entry into the clinic with OPMD asset (BB-301)
- Additional programs could be clinic-ready in late 2019
- Flexibility of ddRNAi platform can potentially accelerate clinical and shareholder value with the ability to move proven ddRNAi therapeutics into additional rare diseases

BENITEC BIOPHARMA

RECENT ACHIEVEMENTS

And path to value creation

Achievements

- Nant Capital makes strategic investment in Benitec to bring in Phase 2 oncology asset (BB-401)
- Phase 2 clinical study of BB-401 in head & neck squamous cell carcinoma (HNSCC) initiated
- US and EU orphan drug designation for oculopharyngeal muscular dystrophy (OPMD)
- Nature Communications publication of initial ‘silence and replace’ preclinical data (OPMD)
- Pre-IND meeting with US FDA, Health Canada and several EU agencies informs a clear path to the clinic for OPMD asset (BB-301)
- Pre-IND meeting with US FDA informed a clear and expeditious path to the clinic for HBV asset
- Australian R&D grant income of A$10.5m for 2017 fiscal year

BENITEC BIOPHARMA

PERMANENT GENE SILENCING

With DNA-Directed RNA Interference (ddRNAi)



- Combines RNA interference with gene therapy delivery
- Long term therapeutic potential from a single administration
- Constant, steady-state levels of shRNA expression
- Silence a single gene or target multiple genes simultaneously
- Simultaneous silencing of disease causing genes with co-expression of normal genes to restore function

BENITEC BIOPHARMA

DIVERSE PROGRAM PIPELINE

Program	Delivery	Discovery	Preclinical	IND-Enabling	Early stage clinical (IND – Ph 2)	Late stage clinical (Ph 2 – Ph 3)	Commercial rights
Oncology – head and neck squamous cell carcinoma (HNSCC)							
HNSCC BB-401	Plasmid Intratumoral						Global
HNSCC BB-501	ddRNAi Intratumoral						Global
Orphan disease - oculopharyngeal muscular dystrophy (OPMD)							
OPMD BB-301	AAV Intramuscular						Global
Infectious disease – hepatitis B (HBV)*							
HBV BB-103	AAV Intravenous						Global
Retinal disease - wet age-related macular degeneration (AMD)							
AMD BB-201	Novel AAV Intravitreal						Global



*Continued development dependent on partnership or funding

BENITEC BIOPHARMA

BENITEC PIPELINE

Program	Delivery	Discovery	Preclinical	IND-Enabling	Early stage clinical (IND – Ph 2)	Late stage clinical (Ph 2 – Ph 3)	Commercial rights
Oncology – head and neck squamous cell carcinoma (HNSCC)							
HNSCC BB-401	**Plasmid Intratumoral**						**Global**
HNSCC BB-501	**ddRNAi Intratumoral**						**Global**
Orphan disease - oculopharyngeal muscular dystrophy (OPMD)							
OPMD BB-301	AAV Intramuscular						Global
Infectious disease – hepatitis B (HBV)							
HBV BB-103	AAV Intravenous						Global
Retinal disease - wet age-related macular degeneration (AMD)							
AMD BB-201	Novel AAV Intravitreal						Global

HEAD AND NECK SQUAMOUS CELL CARINOMA (HNSCC)

Incidence and Patient Mortality:

- Global incidence of 119,000 in 2016 expected to increase to over 136,000 in 2026
- 50% of patients expected to develop recurrent or metastatic disease
- Median overall survival of 7.8 months and five year survival rate of 3.6% for patients with recurrent or metastatic disease
- ***Over 90% of HNSCC lesions overexpress epidermal growth factor receptor (EGFR)***

Unmet Medical Need:

- Significant patient morbidity derived form loco-regional tumor growth and progression in confines of small anatomical space
- Durable tumor reduction or eradication
- Lack of biomarkers to reliably predict response to targeted therapy

Anatomical sites of HNSCC



BB-401: EXPRESSED ANTI-SENSE RNA AGAINST EGFR PHASE 1 SINGLE AGENT CLINICAL DATA

- BB-401 is comprised of plasmid DNA which produces a 39-nt antisense RNA with specificity against EGFR
- Phase I study of 17 patients with advanced, refractory HNSCC
- Safety and efficacy following direct intra-tumoral injection weekly for 4 weeks:
  - 29 % (5 patients) - Objective Response
  - 2 patients experienced Complete Response
  - 3 patients Partial Responses (reduction >30% by RECIST)
  - 2 additional patients - Stable Disease
  - 41% overall disease control rate
  - 6.5 months observed anti-tumor response
- Strong correlation between baseline level of EGFR expression and clinical response



BENITEC BIOPHARMA

BB-401: FOLLOW-ON PHASE I STUDY IN COMBINATION WITH CETUXIMAB AND RADIATION

- 6 patients were treated in a Phase 1 study of BB-401 in combination with radiation and cetuximab
- 5 of 6 patients experienced an Objective Response (83%)
- 4 patients Complete Response & 1 patient Partial Response



Grandis et al, University of Pittsburgh
Poster from ASCO 2015

BENITEC BIOPHARMA

BB-401-01: PHASE 2 CLINICAL STUDY IN HNSCC

Intratumoral BB-401 in patients with recurrent or metastatic head and neck squamous cell carcinoma

Key Entry Criteria

- Histologically or cytologically confirmed HNSCC
- Refractory to all available standard therapies
- At least one lesion amenable to injection
- Performance status (ECOG) 0-2

Multi Center Single Arm Study
Fleming 2 Stage Design

Stage 1:
12 patients

Potential Outcomes

- 0 response
  Stop for futility
- 1-2 responses
  Proceed to Stage 2
- ≥ 3 responses
  Stop for success

Stage 2:
~15 patients

Endpoints after 2 cycles of BB-401
(1 cycle = 4 weekly injections BB-401)

- Overall response rate
- Disease control rate
- Duration of response
- Survival
- Safety
- Quality of Life

Study now open* with value inflection point at end of Stage 1

*Approval in Australia in March 2018

BENITEC BIOPHARMA

HEAD & NECK SQUAMOUS CELL CARCINOMA

Clinical Candidate BB-401: Product Overview

Head & Neck Squamous Cell Carcinoma (HNSCC)	Incidence to increase from 119,000 in 2016 to 136,000 in 2026 with global market estimated to be US$4.1 billion in 2026	Morbidity caused by the spatial effects of tumors in the confined anatomical structures of the head and neck	Over 90% of HNSCC overexpress EGFR
BB-401 Product Profile	EGFR targeted via expressed antisense RNA	In Phase I, strong correlation between BB-401 treatment versus EGFR overexpression	Robust objective response rate versus other monotherapy treatments or when paired with SOC treatments
Value / Commercial Opportunity	<u>Value inflection point at end of stage 1:</u> Phase 2 open label study in up to 30 patients initiated in Q1 2018	Selective direct targeting of malignant lesions could uniquely address the unmet medical need in HNSCC	BB-401 is intended to be paired with diagnostic against EGFR

BENITEC BIOPHARMA

BENITEC PIPELINE

Program	Delivery	Discovery	Preclinical	IND-Enabling	Early stage clinical (IND – Ph 2)	Late stage clinical (Ph 2 – Ph 3)	Commercial rights
Oncology – head and neck squamous cell carcinoma (HNSCC)							
HNSCC BB-401	Plasmid Intratumoral						Global
HNSCC BB-501	ddRNAi Intratumoral						Global
Orphan disease - oculopharyngeal muscular dystrophy (OPMD)							
OPMD BB-301	**AAV Intramuscular**						**Global**
Infectious disease – hepatitis B (HBV)							
HBV BB-103	AAV Intravenous						Global
Retinal disease - wet age-related macular degeneration (AMD)							
AMD BB-201	Novel AAV Intravitreal						Global



BENITEC BIOPHARMA

OPMD DISEASE OVERVIEW

Disease:

- Rare autosomal dominant inheritance
- 1:100,000 (Europe)
- As high as 1:600 in specific populations
- Typical age of onset is late 40's or older

Characterized by:

- Eyelid drooping (ptosis)
- Swallowing difficulty (dysphagia)
- Proximal limb weakness
- Death due to aspiration pneumonia & malnutrition

Histopathology:

- Decrease of muscle fiber number
- Variation in the size of muscle fibers
- Fibrosis (connective tissue)



BENITEC BIOPHARMA

GENETIC BASIS OF OPMD: POLY-ALANINE EXPANSION IN THE PABPN1 GENE

PABPN1:

- A ubiquitous factor that promotes interaction between the poly(A) polymerase and CPSF (cleavage and polyadenylation specificity factor) and thus controls the length of mRNA poly(A) tails, mRNA export from the nucleus, and alternative poly(A) site usage.



In OPMD:

- A genetic mutation results in trinucleotide repeat expansion within exon 1 of PABPN1 and results in an expanded poly-alanine tract at the N-terminal end of PABPN1.



Non-affected



Affected

WT ATG $(GCG)_6$ ----------$(GCA)_3$ GCG GGG GCT GCG..
MUT ATG $(GCG)_6$ $(GCG)_{1-7}$ $(GCA)_3$ GCG GGG GCT GCG…--

BENITEC BIOPHARMA

BB-301: A 'SILENCE AND REPLACE' BASED APPROACH



AAV

- Non-integrating, non-pathogenic viral delivery
- To date, AAV has been used in over 204 clinical trials
- Sustained expression (years) following single injection



← Insensitive to shRNA

BENITEC BIOPHARMA

BB-301 SILENCES MUTANT PABPN1 EXPRESSION AND RESTORES NORMAL PABPN1 IN OPMD MOUSE MODEL





BB-301 REVERSES INTRANUCLEAR INCLUSIONS IN OPMD MOUSE MODEL





*** p ≤ 0.001

BB-301 REVERSES FIBROSIS IN TRANSVERSE MUSCLE SECTIONS IN OPMD MOUSE MODEL





BENITEC BIOPHARMA

BB-301 RESTORES MUSCLE FUNCTION IN OPMD MOUSE MODEL

Restoration of Muscle Force



Restoration of Muscle Weight



BENITEC BIOPHARMA

BB-301: SCALABLE MANUFACTURING

50 Liter Reactor

- Produced with scalable baculovirus based methodologies and purification processes to control cost of goods.
- Using a modified AAV capsid for the generation of highly active BB-301 particles
- Benitec has developed a product specific process for producing high titer, highly pure BB-301:
  - Yields exceed 1e14 vector genomes/liter
  - Recovery yields in final product range from 30 – 40 %
- GMP grade clinical material produced at leading Contract Manufacturing Organization
- Currently manufacturing at 50L scale
- Clinical product to be generated at 250L scale

Silver stain of SDS protein gel
showing output of purification steps
(3 capsid bands expected in final product)

BENITEC BIOPHARMA

BB-301-01: PHASE 1/2A CLINICAL STUDY IN OPMD

Intramuscular BB-301 in OPMD patients with swallowing dysfunction*

Key Entry Criteria

- Aged 35 to 80
- Clinical diagnosis of OPMD
- Genetic diagnosis of OPMD
- Swallowing dysfunction
- No prior myotomy

Multicenter Dose Escalation Study

Cohort 1 – Low Dose
(~3-5 BB-301)

Cohort 2 – Medium Dose
(~3-5 BB-301)

Cohort 3 – High Dose
(~3-5 BB-301)

Maximum Effective Dose
~12 patients BB-301

Endpoints Through 52 Weeks

- Safety & tolerability
- Quantitative clinical improvement in swallowing
- Patient reported improvement in swallowing and quality of life

*Study design and parameters subject to change based on nonclinical toxicology results and clinical and regulatory feedback

BENITEC BIOPHARMA

OPMD: KEY FEATURES IN BB-301 DEVELOPMENT

Non-Clinical:

- OPMD phenotypes (muscle strength, dystrophy, intranuclear inclusions, fibrosis) in A17 mice are reversible
- Initial studies published in Nature Communications
- Ongoing safety and toxicology studies being performed in sheep models

Manufacturing:

- Produced using scalable baculovirus based manufacturing methodologies
- Currently manufacturing at 50L scale
- Clinical product to be generated at 250L scale

Regulatory:

- Orphan Drug Designation granted in EU (2017) and US (2018) which can lower cost of approval, potentially reduce development costs and provide seven year market exclusivity at approval
- Pre-IND meeting and scientific advice meetings completed in US, Canada, UK, France and Denmark
- Two large sheep safety studies requested by regulators – to be completed at end of 2018
- IND submission targeted for Q1 2019

Clinical:

- Direct one time injection of BB-301 into throat muscles for the treatment of OPMD-related dysphagia
- Benitec working hand in hand with key opinion leaders and physicians to define the clinical development plan
- Initial clinical study to start once IND or other regulatory filing is approved

BENITEC BIOPHARMA

OCULOPHARYNGEAL MUSCULAR DYSTROPHY

Clinical Candidate BB-301: Product Overview

Oculopharyngeal muscular dystrophy (OPMD)	Rare, autosomal dominant, heritable monogenic disease	Estimated 12,000 effected patients in Western countries.	Eyelid drooping, swallowing difficulties, proximal limb weakness, death due to aspiration pneumonia and malnutrition
BB-301 Product Profile	Designed to treat dysphagia associated with OPMD	'Silence and Replace' – unique gene therapy mechanism	Silence: mutant PABPN1 gene Replace: Simultaneously introduces normal PABPN1 gene to restore function
Value / Commercial Opportunity	<u>Near term value inflection point:</u> 1Q19 clinic entry Commercial opportunity in excess of US$1 billion	Significant unmet medical need with no direct competition Orphan with cost efficient commercialization path	Potential for silence and replace approach for other monogenic diseases

BENITEC BIOPHARMA

BENITEC PIPELINE

Program	Delivery	Discovery	Preclinical	IND-Enabling	Early stage clinical (IND – Ph 2)	Late stage clinical (Ph 2 – Ph 3)	Commercial rights
Oncology – head and neck squamous cell carcinoma (HNSCC)							
HNSCC BB-401	Plasmid Intratumoral						Global
HNSCC BB-501	ddRNAi Intratumoral						Global
Orphan disease - oculopharyngeal muscular dystrophy (OPMD)							
OPMD BB-301	AAV Intramuscular						Global
Infectious disease – hepatitis B (HBV)							
HBV BB-103	**AAV Intravenous**						**Global**
Retinal disease - wet age-related macular degeneration (AMD)							
AMD BB-201	Novel AAV Intravitreal						Global

*Continued development dependent on partnership or funding

BENITEC BIOPHARMA

BB-103 POSITIONS INHIBITORY shRNA ACROSS WELL CONSERVED SEQUENCES IN THE HBV GENOME



* Sequences selected for shRNA are well conserved across HBV genotypes A-H

BENITEC BIOPHARMA

BB-103 BUILDS UPON THE LEARNINGS FROM BENITEC'S FIRST IN MAN TRIAL WITH TT-034 IN HCV



Safety and Efficacy Study in Single Doses of TT-034 in Patients with Chronic Hepatitis C
Clinical Trials.gov Identifier: NCT10899092

BENITEC BIOPHARMA

PXB MOUSE, A CHIMERIC ANIMAL WITH A LIVER HIGHLY REPLACED BY HUMAN HEPATOCYTES

1. Human hepatocytes proliferating under physiologically relevant conditions
2. Histologically normal liver constitution
3. Human specific metabolism and excretion pathways
4. Infectable with HBV and HCV



cDNA-uPA/SCID
Liver weight: 0.7 – 1 g

Transplantation



PXB-Mouse®
Liver weight: 2 – 2.5 g
(RI: 98 %)

PhoenixBio

BENITEC BIOPHARMA

IN VIVO INFECTIOUS STUDIES USING PXB MICE

Chimeric mouse with humanized liver

2. Incubate mice for 4 weeks, establish baseline HBV infection, randomize

HBV infected Chimeric mouse

3. Transduce mice with BB-103



1. Infect chimeric PXB mice with HBV genotype C

4. Administer Entecavir (Daily)

5. Follow infected mice for an additional 91 days

RNA (terminal):

HBV viral transcripts
Production of anti-HBV shRNA

Serum (weekly):

Extracellular HBsAg
Extracellular HBeAg
Extracellular HBV DNA
Human Albumin

DNA (terminal):

Total Intracellular DNA (control)
Intracellular HBV DNA
HBV cccDNA

BENITEC BIOPHARMA

A SINGLE DOSE OF BB-103 + DAILY ENTECAVIR RESULTS IN >4 LOG SUPPRESSION OF HBV DNA AND >2 LOG HBsAg

Reduction in HBV serum DNA



Reduction in HBsAg (s-antigen)



BENITEC BIOPHARMA

BB-103 + ENTECAVIR REDUCES HBV VIRAL RNA BY > 99%

	Total HBV Reads (per 1M reads)	Reads Normalized to RNA Length (per 1kb)		
		pgRNA (3.5Kb)	PreS1/S2 mRNA (2.4/2.1 Kb)	X RNA (0.7kb)
Untreated	1674	435	171	112
BB-101	457	119	45	31
BB-101+ETV	72	19	8	5
BB-103	122	30	12	9
BB-103+ETV	13	3	2	1



Untreated
BB-101
BB-101+ETV
BB-103
BB-103+ETV

Max Read Depth: 136

HEPATITIS B

Clinical Candidate BB-103: Product Overview

Hepatitis B (HBV)	WHO estimates HBV infects 257 million people resulting in up to 780,000 deaths per year	HBV viral proteins, especially HBsAg causes hepatic inflammation, liver dysfunction, acute hepatic failure, cirrhosis, or HCC	Need for effective therapies that promote restoration of a host immune response through targeted HBsAg knockdown
BB-103 Product Profile	Designed as a single dose treatment to be added on top of existing SOC	Designed against well conserved sequences in all major HBV genotypes	Superior efficacy: BB-103 combined with ETV showed a >4 log drop in HBV DNA and >2 log drop in HBsAg
Value / Commercial Opportunity	<u>Near term value inflection point</u>: With partnership or funding could be clinic ready late in 2019	Pre-IND FDA meeting informed a clear and expeditious path to the clinic	Leverages use of TT-034 clinical data, Benitec's first in man HCV study

BENITEC BIOPHARMA

PROGRAM SUMMARY

BB-401:
Oncology (HNSCC)

- EGFR antisense asset (BB-401) entered clinic in 1Q18 in P2 study in recurrent or metastatic HNSCC
- Discovery stage program using proprietary ddRNAi platform, to develop follow-on anti-EGFR strategies (BB-501)

BB-301:
Orphan disease (OPMD)

- Unique single vector 'silence and replace' mechanism
- Pre-IND meetings complete in US and EU
- IND filing planned 1Q 2019
- Commercial opportunity in excess of US$1 billion

BB-103:
Infectious disease (HBV)

- Preclinical POC with significant reduction in viral load and HbsAg when combined with SOC
- Pre-IND April 2017 informed direct path to clinic entry
- Seeking partnerships to move into the clinic

BB-201:
Retinal disease (AMD)

- Novel viral capsids for delivery to retinal cells via intravitreal injection
- Molecular analyses ongoing from PoC study in NHP – additional work required to progress BB-201 in AMD
- Possible delivery platform for other retinal diseases

BENITEC BIOPHARMA

INVESTMENT HIGHLIGHTS

Novel combination of gene therapy and gene silencing

- BB-401 (oncology) in clinic with Phase 2 study. BB-301 (OPMD) in clinic early 2019
- Validated ddRNAi technology, with human safety data
- Robust pipeline in oncology, orphan genetic disorders, retinal disease and infectious disease

Capital market access

- Listed on ASX (BLT) and NASDAQ (BNTC)
- US$50M capital raised since 2014
- US shelf registration statement filed

Strong in-house capabilities

- Deep gene therapy expertise
- In-house manufacturing expertise for process optimization and scalability

BENITEC BIOPHARMA

BENITEC BIOPHARMA

NASDAQ: BNTC | ASX: BLT

CONTACT:
info@benitec.com